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Treatment Outcomes of Sunitinib Treatment 
in Advanced Renal Cell Carcinoma Patients: 
A Single Cancer Center Experience in Korea
I n t r o d u c t i o n
Renal cell carcinoma (RCC) represents 2?3% of all tumors with
an incidence which is increasing annually (1). Up to 30% of RCC
patients present in an advanced state, and approximately 40% of
patients who undergo curative surgical resection experience
recurrence during the follow-up (2,3). Though cytokine treatment
with interleukin-2 or interferon-alpha has been widely used as a first-
line treatment of metastatic RCC, it has shown a modest survival
benefit and a poor quality of life (4). Therefore, alternative agents
with greater efficacy and less toxicity are needed for the systemic
treatment of renal cell carcinoma. Remarkable improvement in
understanding the biology and genetics of RCC has facilitated the
novel target-based approaches for the treatment of metastatic RCC.
Sunitinib is an orally available, multi-targeted tyrosine kinase
inhibitor which specifically interferes with platelet-derived growth
factor receptor and vascular endothelial growth factor receptor (5).
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Purpose
The retrospective study was performed to assess the efficacy and toxicity profiles of
sunitinib in Korean patients with metastatic renal cell carcinoma (RCC).
Materials and Methods
Between January 2005 and December 2008, 76 Korean patients with recurrent/metastatic
RCC who received sunitinib were retrospectively reviewed. The primary end point was
progression-free survival and the secondary end points were overall survival and response
rate. We also assessed the toxicities associated with sunitinib treatment.
Results
Of the 76 patients, 69 (90.1%) were diagnosed with clear cell RCC. The median progression-
free survival and overall survival were 7.2 and 22.8 months, respectively in overall patients.
Sixty-two patients (81.6%) received 50 mg 4 week and 2 week off schedule, and 14 patients
(18.4%) received 37.5 mg daily on a daily continuous schedule. The objective response rate
and disease control rate were 27.6% and 84.2%, respectively. A dose reduction or reduction
in dose due to adverse events occurred in 76% of the patients, whereas 11% of the patients
had discontinued treatment. Other common laboratory abnormalities were increased serum
creatinine (75.6%), elevated alanine aminotransferase (71.0%), neutropenia (61.8%), anemia
(69.7%), and increased aspartate aminotrasferase (53.3%). Grade 3/4 toxicities occurred as
follows: thrombocytopenia (38.2%), fatigue (10.5%), stomatitis (10.5%), and hand-foot
syndrome (9.2%).
Conclusion
Our results indicate that sunitinib treatment is effective and tolerable for ecurrent/metastatic
RCC patients in Korea. Further studies with prognostic or biochemical factors are needed to
clarify the different toxicity profiles of this study.
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These receptor tyrosine kinases are known to play important roles in
the pathogenesis of RCC (6,7). In phase III trials, this agent was
shown to significantly improve the median progression-free survival
(PFS), and yield a higher response rate (RR), and afford a better
quality of life over interferon-alfa (8). However, these studies were
performed mainly in Western populations. Therefore, further studies
about the efficacy and safety profiles are needed for involving
Asian RCC treated with sunitinib. 
We retrospectively performed this descriptive study to assess the
efficacy and toxicity profiles of sunitinib to determine whether there
is a difference in Korean patients with metastatic RCC compared to
Western patients.
M a t e r i a l s  a n d  M e t h o d s
1 Patients
The medical records of RCC patients with recurrent or metastatic
disease who had received sunitinib treatment at the Yonsei
University Health System (YUHS) between January 2005 and
December 2008 were retrospectively reviewed. The inclusion
criteria were as follows; Asian ethnicity, metastatic RCC treated
with sunitinib, and patients with available medical data for
evaluating efficacy and toxicity. Clinicopathologic factors such as
age, gender, tumor histology, Eastern Cooperative Oncology Group
performance status (ECOG PS), the number of prior treatments,
sites of metastasis, laboratory findings, and patient survival were
collected retrospectively and analyzed. We also assessed the
Memorial Sloan-Kettering Cancer Center (MSKCC) risk scoring
system according to a previous study (9). 
2 Sunitinib treatment
Sunitinib was prescribed as a part of clinical or non-clinical trials
with 2 different schedules: group 1, 50 mg orally once daily for 4
weeks followed by a 2 week rest period (50 mg 4 weeks on - 2
weeks off schedule); and group 2, 37.5 mg daily continuous dosing.
For the evaluation of the response, Response Evaluation Criteria In
Solid Tumors (RECIST) was applied (10). Regular physical
examinations and computed tomography or magnetic resonance
imaging were performed for treatment outcome every 6?8 weeks.
Toxicity was evaluated during the sunitinib treatment according to
the National Cancer Institute common toxicity criteria (version 3.0).
3 Statistical analysis
Survival analysis was calculated using the Kaplan-Meier method
with Statistical Package for the Social Sciences (SPSS), version
15.0. PFS was defined from the date of the 1st dose of sunitinib to
the death of any cause or disease progression. Overall survival (OS)
was defined from the date of the 1st dose of sunitinib to the death of
any cause. We also analyzed the 1-year PFS rate and OS rates.
Toxicities were estimated as simple proportions. 
R e s u l t s
1 Patient characteristics
Seventy-six RCC patients were included in the analysis (Table 1).
The median age was 57.5 years (range 29?73 years), and the
patients consisted of 63 males (82.9%) and 13 females (17.1%).
Sixty-five patients (85.5%) were diagnosed with clear cell RCC and
the others diagnosed with papillary (n=4), chromophobe (n=2), and
mixed cell types (n=4; 2 patients with clear cell combined with
papillary cell, 1 patient with clear cell combined with granular cell,
and 1 patient with sarcomatoid type combined with clear cell). The
distribution of MSKCC scores of 60 patients with evaluable data
were as follows: favorable for 7 patients (11.6%), intermediate for
47 patients (78.3%), and poor for 6 patients (10%). The previous
treatments were as follows: previous nephrectomy in 72 patients
(94.7%), conventional chemotherapy in 16 patients (21.1%),
cytokine treatment in 42 patients (55.3%), targeted agent in 7
patients (9.2%), and radiotherapy in 16 patients (21.1%). The
number of patients who underwent nephrectomy as a curative aim
was 35 (46.1%) and pathologic staging in completely resected
patients was as follows: stage I for 6 (24.0%), stage II for 8 (32.0%),
stage III for 9 (36.0%), and stage IV for 2 (8.0%) with available
pathologic data (25 patients). The metastatectomy was performed in
4 patients and it included lung segmentectomy, retroperitoneal
lymphadenocetomy, colon resection and splenectomy with distal
pancreatectomy. 5 patients were treated with sorafenib and two with
erlotinib/ bevacizumab before sunitinib treatment. Number of
disease sites was as follows: 0 for 1 patient (1.3%), 1 for 17 patients
(22.4%), 2 for 25 patients (32.9%), and ?2 for 34 patients (43.4%),
respectively. Most prevalent site of metastasis were the lung (56
patients [73.7%]) followed by the lymph nodes (36 patients
[47.4%]), bone (29 patients [38.2%]), and liver (8 patients [10.5%]).
2 Treatment summary and survival outcome
Two different settings in the treatment schedule existed. The
majority of the patient (n=62 [81.6%]) received the standard
regimen of 50 mg 4 weeks on - 2 weeks off schedule, and 14
patients (18.4%) received the 37.5 mg daily schedule. The number
of the patients who received sunitinib as a first-line systemic
treatment were 31 (40.8%). After a median of 16.0 months (range,
0.5?40.1 months) of follow-up, 34 patients (44.7%) remained alive
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with diseases. The median treatment duration was 7.2 months
(range, 0.5?35.7 months), and treatment is ongoing in 10 patients
(13.2%). The reasons for treatment discontinuation were progressive
disease (n=54 [81.8%]), and adverse events (n=7 [10.6%]). Other
reasons of dose discontinuation included withdrawal of consent (4
patients) and loss to follow-up.
The median PFS was 7.2 months (95% confidence interval [CI],
4.7?9.7 months, Fig. 1), and the median OS was 22.8 months
(95% CI, 18.7?26.9 months, Fig. 2). The 1-year PFS rate and 1-
year OS rate were 36.8% (95% CI, 26.1?48.7%) and 61.8% (95%
CI, 50.0?72.6%), respectively. Of the 786 evaluable patients,
objective RR (including complete and partial responses) was 27.6%
(95% CI, 18.0?39.1%) and the disease control rate (including
complete response, partial response, and stable disease) was 84.2%
(95% CI, 74.0?91.6%), as shown in Table 2. In 10 non-clear cell
type RCC patients, 1 patient had a partial response (10%) and
disease control was achieved in 8 patients. The median PFS was 5.1
months (95% CI, 4.2?6.0 months) and the median OS was 9.0
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*Data of cell type in one patient was missing.?Eastern Cooperative Oncology
Group, ?Risk factors in Memorial Sloan-Kettering Cancer Center (MSKCC) risk
scoring system are a low hemoglobin level, an elevated corrected calcium level,
an elevated serum lactate dehydrogenase level, a poor performance status and an
interval of less than 1 year between diagnosis and treatment. The MSKCC risk
factors could not be calculated in 20 patients due to incomplete data.
Characteristics Number (%)
Total patients 76 (100)
Gender
Male 63 (82.9) 
Female 13 (17.1)
Median age-year (range) 57.5 (29~73)
Histology
Clear 65 (85.5)
Non-clear cell type 10 (13.2)
Unknown 1 (1.3)
ECOG performance status?
0 28 (36.8)
1 40 (52.6)
2 8 (10.5)
Number of disease sites
0 1 (1.3)
1 17 (22.4)
2 25 (32.9)
?3 33 (43.4)
MSKCC risk factors?
0 (favorable) 7 (11.6)
1, 2 (intermediate) 47 (78.3)
?3 (poor) 6 (10)
Sites of metastasis
Lung 56 (73.7)
Liver 8 (10.5) 
Bone 29 (38.2)
Lymph nodes 36 (47.4)
Previous treatment
Systemic Treatment 45 (59.2)
Cytotoxic agent 16 (21.1)
Cytokine 42 (55.3)
Target agent 7 (9.2)
Nephrectomy 72 (94.7)
Radiotherapy 16 (21.1)
Number of previous systemic treatment
0 31 (40.8)   
1 32 (42.1)
2 8 (10.5)
?3 5 (6.5)
Schedule
50 mg 4 weeks on - 2 weeks off 62 (81.6)
37.5 mg daily 14 (18.4)
Table 1. Patient characteristics
Fig. 1. Progression-free survival in Korean patients with metastatic
renal cell carcinoma.
Fig. 2. Overall survival in Korean patients with metastatic renal cell
carcinoma.
months (95% CI, 0.5?17.4 months) in the non-clear cell patients.
In addition, in the subgroup who had prior targeted agent treatment
(7 patients), 6 patients reached stable disease with 1.5 months (95%
CI 0.0?6.7 months) of the median PFS and 12.0 months (95% CI,
1.4?22.5 months) of the median OS. We also evaluated the
difference between dosing schedule. The response rate was 25.8%
and the disease control rate was 82.3% in the 50 mg 4 weeks on - 2
weeks off dosing schedule, as compared with 35.7% and 92.9%,
respectively, in the 37.5 mg daily treatment schedules (Table 2). The
median PFS in both the standard and other dosing schedules was 7.2
months.
3 Toxicity
A total 76% of the patients had a dose interruption or dose
reduction due to adverse events, whereas only 11% of patients
discontinued treatment due to toxicity. Stomatitis and diarrhea were
the most commonly reported treatment-related adverse events
(63.2% and 60.5%, respectively), but the rate of severe cases with
grade 3 or more was not prevalent (10.5% and 6.6%, respectively),
as shown in Table 3. Adverse events which were reported with a ?
50% frequency were fatigue (57.9%), anorexia (59.2%) and hand-
foot syndrome (52.6%). A decrease in the left ventricular ejection
fraction of grade 1 was reported in only 1 case, and was without
clinical significance. Thyroid function tests were conducted in 45
patients. Eleven cases (24.4%) of hypothyroidism were noted, and 8
(17.8%) patients needed thyroid hormone replacement. In addition,
we did not observev hemolytic uremic syndrome or thrombotic
thrombocytopenia purpura in this group of patients (11).
The most common laboratory abnormality was thrombocytopenia
(77.6%), and 38.2% of the patients experienced grade 3 or 4
thrombocytopenia, which was no clinical significance (such as
bleeding; Table 4). Other common laboratory abnormalities were
increased serum creatinine (75.6%), elevated alanine amino-
Cancer Res Treat. 2009;41(2):67-72
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Treatment-related
All grades Grade 3 or 4
adverse events, no. (%)
Stomatitis/mucositis 48 (63.2) 8 (10.5)
Diarrhea 46 (60.5) 5 (6.6)
Anorexia 45 (59.2) 2 (2.6)
Fatigue 44 (57.9) 8 (10.5)
Skin discoloration 41 (53.9) 0 (0)
Hand-foot syndrome 40 (52.6) 7 (9.2)
Rash 34 (44.7) 4 (5.3)
Nausea 32 (42.1) 2 (2.6)
Dyspepsia 27 (35.5) 2 (2.6)
Periorbital edema 27 (35.5) 0 (0)
Facial edema 27 (35.5) 0 (0)
Generalized edema 19 (25.0) 0 (0)
Constipation 17 (22.4) 1 (1.3)
Taste alternation 16 (21.1) 0 (0)
Vomiting 16 (21.1) 1 (1.3)
Dyspnea 15 (19.7) 0 (0)
Epistaxis 13 (17.1) 0 (0)
Hypertension 12 (15.8) 1 (1.3)
Abdominal pain 8 (10.5) 1 (1.3)
Pruritis 8 (10.5) 0 (0)
Alopecia 3 (3.9) 0 (0)
Decrease in left ventricular 1 (1.3) 0 (0)
ejection fraction
Hypothyroidism? 11 (24.4) 1 (2.2)
Table 3. Treatment-related adverse events
*These data were available on selected 45 patients.
Table 2. Best tumor response*
50 mg 4 weeks 37.5 mg
Number (%) Total (n=76) on - 2 weeks daily
off (n=62) (n=14)
Objective response 21 (27.6) 16 (25.8) 5 (35.7)
Complete response 1 (1.3) 1 (1.6) 0 (0)
Partial response 20 (26.3) 15 (24.2) 5 (35.7)
Stable disease 43 (56.6) 35 (56.5) 8 (57.1)
Disease control rate 64 (84.2) 51 (82.3) 13 (92.9)
*Tumor response was assessed according to the Response Evaluation Criteria in
Solid Tumors (RECIST).
Table 4. Treatment-related laboratory abnormalities
Laboratory 
abnormality, no. (%) All grades Grade 3 or 4
Hematologic toxicity (n=76) 
Leukopenia 47 (61.8) 14 (18.4)
Anemia 53 (69.7) 18 (23.7)
Thrombocytopenia 59 (77.6) 29 (38.2)
Neutropenia 54 (71.1) 22 (28.9)
Non-hematologic toxicity (n=45)
Increased creatinine 34 (75.6) 15 (33.3)
Increased aspartate 24 (53.3) 3 (6.6)
aminotransferase
Increased alanine 32 (71.0) 7 (15.5)
aminotransferase
Increased total bilirubin 22 (48.9) 7 (15.5)
Hypophosphatemia 16 (35.6) 2 (4.4)
Hyponatremia 6 (13.3) 6 (13.3)
Hypernatremia 20 (44.4) 8 (17.8)
Hypokalemia 5 (11.1) 0 (0)
Hyperkalemia 8 (17.8) 2 (4.4)
Hypercholesterolemia 6 (13.3) 1 (2.2)
Proteinuria 19 (42.2) 0 (0)
Increased amylase 16 (35.6) 6 (13.3)
Increased lipase 1 (2.2) 0 (0)
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transferase (71%), neutropenia (71.1%), anemia (69.7%), and
increased aspartate aminotrasferase (53.3%). Grade 3 or 4
hyperamlyasemia was reported in 13.3% of patients, but no signs of
clinical pancreatitis were observed.
D i s c u s s i o n
RCC is one of the malignancies with a dismal prognosis because
of the modest response to conventional chemotherapeutic agents
and cytokine therapy. With the elucidation of the molecular
pathogenesis of RCC, sunitinib, one of the molecular targeted agents
was introduced for the treatment of metastatic RCC (8,12). Previous
studies have confirmed the promising efficacy of sunitinib as a
standard first-line treatment for metastatic clear cell RCC (8,12).
However, these studies were mainly performed for patients in
Western countries. Only one small study was reported for Asian
patients with RCC who were treated with sunitinib (13), thereby the
potential ethnic difference in the efficacy and toxicity of sunitinib
have not been established. This retrospective study showed that
homogeneous Asian patients with metastatic or recurrent RCC who
received sunitinib had comparable survival outcome with patients in
previous randomized studies. 
For the treatment outcome, the median PFS and OS were 7.2 and
22.8 months, respectively. We also showed a 27.6% objective
response rate and an 84.2% disease control rate in this analysis.
Previous global trials have demonstrated 8.3 and 11 months of the
median PFS and objective response rate of 34% and 31% (8,12).
Even though it is difficult to compare this retrospective study with
previous phase III randomized trials, we observed that metastatic
RCC patients in our study also benefitted from sunitinib treatment.
Interestingly, in our study, more patients with poor prognostic
factors were included. In terms of MSKCC risk group, 88.3% of
patients were in the intermediate or poor groups in this study. In
addition, unlike the reported randomized studies, ?50% of patients
had an ECOG PS 1, and 8 (10.5%) patients with an ECOG PS 2
were also included. Therefore, considering the selection bias of
randomized controlled trials which includes relatively better
performance status, this finding may reflect more reliable results in
real clinical practice with possible benefit from sunitinib treatment
for metastatic RCC patients.
In terms of non-hematologic toxicity profiles, stomatitis was the
most frequent adverse event in our study, which accounted for
63.2% of the cases; however grade 3 or 4 stomatitis accounted for
10.5% and was manageable. Meanwhile, more stomatitis and hand-
foot syndrome were noticed in our study compared to the global
trials. For hand-foot syndrome, a much higher rate of all grades and
grade 3/4 toxicities (52.6% of all grades, 9.2% of grade 3 or 4) were
noted in contrast to the previous trials (15?20% of all grades; 1?
7% of grade 3 or 4). Similarly, for stomatitis, a much higher toxicity
(63.2% of all grades; 10.5% of grade 3/4) was noted than in
previous trials (13?25 % of all grades; 1?5 % of grade 3 or 4). 
Hematologic toxicity, especially for thrombocytopenia, was more
remarkable in this study. All grades of thrombocytopenia were
77.6%, and it was similar with Western data (8,12). However,
patients in the present study experienced a much higher rate of grade
3 or 4 thrombocytopenia (38.2% in YUHS data versus 8% in the
randomized phase III trial, respectively). In addition,
thrombocytopenia was the most common cause of dose reduction,
delay, and discontinuation in our study. Other grade 3 or 4
hematologic toxicities such as neutropenia (28.9%), anemia
(23.7%), and leukopenia (18.4%) were also more frequent than in
Western analyses. This finding was consistent with Japanese study
involving sunitinib treatment (13). Whether this toxicity is directly
related to host factors such as poor PS, or prior numbers of
treatments remains uncertain. A disparity in the toxicity profiles
between Eastern and Western countries has been in colon cancer
patients who received capecitabine (14-16). Compared to
Caucasians, a higher incidence of hand-foot syndrome and a lower
rate of diarrhea occurred in non-Caucasian patients treated with
capecitabine, suggesting an ethnic difference between Western and
Eastern patients. As shown in patients receiving capecitabine
treatment, this finding may be caused by ethnic differences.
Therefore, these descriptive results should be interpreted cautiously
and further study with a larger sample size and pharmacokinetic
tests are needed to clarify this finding.
The current single center retrospective analysis had several
limitations. The patients in this retrospective study consisted of a
heterogenous population. Thirteen percent of the patients had non-
clear cell RCC, and 9% of all patients had already received targeted
agents before sunitinib. 
Nevertheless, this study represents one of the few studies in which
sunitinib treatment was evaluated for efficacy and toxicity in Asian
patients with RCC. Our results indicated that sunitinib treatment was
effective and tolerable in Korean patients with metastatic RCC.
Further studies with biochemical data would further clarify the
clinical significance of theses findings.
C o n c l u s i o n
This study assessed sunitinib treatment for recurrent/metastatic
Korean patients with RCC in terms of efficacy and toxicity. PFS,
OS, and RR in Korean patients was compatible to Western patients,
although some toxicities in Korean patients were more frequent and
severe, but were manageable.
Cancer Res Treat. 2009;41(2):67-72
72 CANCER  RESEARCH  AND  TREATMENT
1. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and
prevalence across five continents: defining priorities to reduce cancer disparities in
different geographic regions of the world. J Clin Oncol. 2006;24:2137-50.
2. Jemal A, Murray T, Ward E, Samuels A, Tiwari R, Ghafoor A, et al. Cancer statistics,
2005. CA Cancer J Clin. 2005;55:10-30.
3. Janzen NK, Kim HL, Figlin RA, Belldegrun AS. Surveillance after radical or partial
nephrectomy for localized renal cell carcinoma and management of recurrent disease.
Urol Clin North Am. 2003;30:843-52.
4. Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol.
2007;25:884-96.
5. Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM. SU11248 Inhibits KIT and
platelet-derived growth factor receptor ?‚ in preclinical models of human small cell lung
cancer. Mol Cancer Ther. 2003;2:471-8.
6. Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, Li H, et al. Mutations of the VHL
tumour suppressor gene in renal carcinoma. Nat Genet. 1994;7:85-90.
7. Iliopoulos O, Levy AP, Jiang C, Kaelin WG Jr, Goldberg MA. Negative regulation of hypoxia-
inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci USA. 1996;93:10595-9.
8. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al.
Sunitinib versus interferon ?in metastatic renal-cell carcinoma. N Engl J Med. 
2007;356:115-24.
9. Motzer RJ, Bacik J, Schwartz LH, Reuter V, Russo P, Marion S, et al. Prognostic factors 
for survival in previously treated patients with metastatic renal cell carcinoma. J Clin
Oncol. 2004;22:454-63.
10. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al.
New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer
Inst. 2000;92: 205-16.
11. Choi MK, Hong JY, Jang JH, Lim HY. TTP-HUS associated with sunitinib. Cancer Res
Treat. 2008;40:211-3.
12. Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, et al. Sunitinib in
patients with metastatic renal cell carcinoma. JAMA. 2006;295:2516-24.
13. Uemura H, Shinohara N, Naito S, Akaza H. A phase II study of the efficacy and safety
of sunitinib in treatment-naive and pretreated Japanese patients (pts) with metastatic
renal cell carcinoma (mRCC). J Clin Oncol. 2008;26:15S (Abstr 16108). 
14. Law CC, Fu YT, Chau KK, Choy TS, So PF, Wong KH. Toxicity profile and efficacy of
oral capecitabine as adjuvant chemotherapy for Chinese patients with stage III colon
cancer. Dis Colon Rectum. 2007;50:2180-7.
15. Yen-Revollo JL, Goldberg RM, McLeod HL. Can inhibiting dihydropyrimidine
dehydrogenase limit hand-foot syndrome caused by fluoropyrimidines? Clin Cancer
Res. 2008;14:8-13.
16. Saif MW, Sandoval A. Atypical hand-and-foot syndrome in an African American
patient treated with capecitabine with normal DPD activity: Is there an ethnic
disparity? Cutan Ocul Toxicol. 2008;27:311-5.
R e f e r e n c e s
